PENNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Penumbra Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$322.41+1.55 (+0.48%)
Close on Oct 19, 2026
- Market cap
- $12.76B
- P/E (TTM)
- 79.2
- Dividend yield
- –
Share price
+$73.41 (+29.48%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Penumbra Inc grew revenue 17.6% to $1.50B over the twelve months to Jun 30, 2026. Operating income rose 17.6% to $187.34M, moving the operating margin from 12.4% to 12.4%. Free cash flow was $215.91M, up 33.6% from a year earlier.
Revenue
$1.50B
+17.6% vs. a year earlier
Operating income
$187.34M
+17.6% vs. a year earlier
Free cash flow
$215.91M
+33.6% vs. a year earlier
EPS, diluted
$4.07
+9.4% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $12.76B
- P/E ratio
- 79.2
- Price to sales
- 8.48
- Price to book
- 8.33
- Dividend yield
- –
- Free cash flow yield
- 1.69%
Fundamentals
- Revenue
- $1.50B
- Net income
- $160.59M
- EPS, diluted
- $4.07
- Free cash flow
- $215.91M
- Book value per share
- $38.68
- Diluted shares
- 40M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$1.50B+17.6% YoY
Gross profit
$1.02B+20.0% YoY
Operating income
$187.34M+17.6% YoY
Net income
$160.59M+8.7% YoY
EPS, diluted
$4.07+9.4% YoY
Free cash flow
$215.91M+33.6% YoY
Reported periodTrailing twelve months